Caprelsa 2017 U.S. Promotional Audit Report - ResearchAndMarkets.com

September 12, 2018

DUBLIN--(BUSINESS WIRE)--Sep 12, 2018--The “Caprelsa 2017 U.S. Promotional Audit Report” report has been added to ResearchAndMarkets.com’s offering.

The 5 Key Questions Addressed by this Report:

How many physicians were reached by Caprelsa through reportable promotional activity in 2017 and how does this compare to its peer set in the Thyroid Cancer market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does Sanofi’s depth of coverage vary within key specialties (e.g., Endocrinology, Hematology/Oncology, Internal Medicine, Otolaryngology, and Radiation Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians? How often are physicians receiving paid meals for Caprelsa throughout the year (e.g., monthly, quarterly, annually)? Who were the most frequent meal recipients and top paid speakers for Caprelsa in 2017?

Data Sources and Methodology:

The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals. Over 600 paid interactions across 400 physicians made on behalf of Caprelsa were carefully examined to support our analysis. For more information about this report visit https://www.researchandmarkets.com/research/h6q9bc/caprelsa_2017_u_s?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180912006040/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Thyroid Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/12/2018 04:13 PM/DISC: 09/12/2018 04:13 PM


Update hourly